The Technical AnalystExchange: SHZ Sector: Healthcare Industry: Drug Manufacturers—Specialty & Generic
Betta Pharmaceuticals Price, Forecast, Insider, Ratings, Fundamentals & Signals
4.72% CNY43.70
America/New_York / 6 mai 2024 @ 01:22
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 18 288 mill |
| EPS: | 0.940 |
| P/E: | 46.49 |
| Earnings Date: | May 15, 2024 |
| SharesOutstanding: | 418.49 mill |
| Avg Daily Volume: | 5.88 mill |
| RATING 2024-05-06 |
|---|
| A- |
| Buy |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Sell | |
| Return On Equity: | Neutral | |
| Return On Asset: | Buy | |
| DE: | Buy | |
| P/E: | Strong Buy | |
| Price To Book: | Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | 1/24 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 1.30x |
| Company: PE 46.49 | sector: PE 35.84 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| 1.02x |
| Company: PE 46.49 | industry: PE 45.57 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
CNY-22.40 (-151.27%) CNY-66.10 |
| Date: 2024-05-05 |
| Expected Trading Range (DAY) |
|---|
|
CNY 42.17 - 45.25 ( +/- 3.52%) |
| ATR Model: 14 days |
Live Trading Signals (every 1 min)
10.00
Buy
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | CNY43.70 (4.72% ) |
| Volume | 7.80 mill |
| Avg. Vol. | 5.88 mill |
| % of Avg. Vol | 132.49 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For 300558.SZ
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
300558.SZ
Betta Pharmaceuticals Co., Ltd. researches and develops, manufactures, and markets medicines for the treatment of cancer in China. The company offers Icotinib hydrochloride, an oral epidermal growth factor receptor tyrosine kinase inhibitor, which is used to treat non-small-cell lung cancer; and Ensartinib hydrochloride, an anaplastic lymphoma kinase inhibitor for the treatment of non-small cell lung cancer. Betta Pharmaceuticals Co., Ltd. was founded in 2003 and is headquartered in Hangzhou, China.